
    
      36 subjects will receive Xolair, and 8 subjects will receive placebo. The study will occur at
      4 sites: Boston Children's Hospital, Children's Hospital of Philadelphia, Stanford University
      and Lurie Children's Hospital.

      Patients will be pre-treated with Xolair or placebo before rapid oral peanut desensitization.
      Patients will continue to receive Xolair during the 8 subsequent weeks of desensitization,
      receiving their final dose of Xolair one week after reaching the highest tolerated dose of
      peanut.
    
  